Fluvastatin: effects beyond cholesterol lowering (Q34126048)

31 July 2017

1 reference

title

Fluvastatin: effects beyond cholesterol lowering (English)

1 reference

31 July 2017

A Corsini

1

1 reference

31 July 2017

1 July 2000

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

31 July 2017

1 reference

31 July 2017

5

1 reference

31 July 2017

3

1 reference

31 July 2017

161-175

1 reference

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

31 July 2017

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Systematic review on the risk and benefit of different cholesterol-lowering interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Fluvastatin: a review of its use in lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Review of recent clinical trials of lipid lowering in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Effect of fluvastatin on low-density lipoprotein peak particle diameter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Nitric oxide: mediator, murderer, and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Risk-reduction therapy: the challenge to change. Presented at the 68th scientific sessions of the American Heart Association November 13, 1995 Anaheim, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Molecular bases of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Increased platelet sensitivity and thromboxane B2formation in type-II hyperlipoproteinaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Platelet formation of 12-hydroxyeicosatetraenoic acid and thromboxane B2 is increased in type IIA hypercholesterolemic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Proteins derived from platelet alpha granules modulate the uptake of oxidized low density lipoprotein by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Prospective study of endogenous tissue plasminogen activator and risk of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Effets of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107424840000500304

10.1177/107424840000500304

21 January 2018

Identifiers

DOI

0 references

PubMed ID

11150405

1 reference

PubMed ID

11150405